Return to Listing

3 result(s) for Taxotere

PI Name Protocol # Title
Jeremy Cetnar IRB00011046 [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Khaled Tolba IRB00012012 A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy In Patients With Completely Resected STAGE IB−IIIA Non-Small Cell Lung Cancer
Gina Vaccaro STUDY00015439 A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080